Clinical Trials Logo

Filter by:
  • Not yet recruiting  
  • Page [1]
NCT ID: NCT06365632 Not yet recruiting - Abdominal Adhesions Clinical Trials

Clinical Study of the Effectiveness, Tolerability and Safety of the Drug "Anti-spike, Gel, 100 g in Bottles in Package No. 1" Produced by the Republican Unitary Enterprise "Unitekhprom BSU", With a Single Intraperitoneal Use After Surgery in Adult Patients With Acute Phlegmonous Appendicitis

OLTOSPAN-02
Start date: July 2024
Phase: Phase 2
Study type: Interventional

The purpose of the clinical trials is the evaluation of the effectiveness and safety of a single intraperitoneal use of the drug "Antispike, gel, 100 g in a bottle" produced by Unitary Enterprise Unitehprom BSU, Belarus in patients after surgical control of acute phlegmonous appendicitis to prevent abdominal adhesions.

NCT ID: NCT06232434 Not yet recruiting - Clinical trials for Gastric Cancer With Peritoneal Dissemination

An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II

???????-02
Start date: June 2024
Phase: Phase 2/Phase 3
Study type: Interventional

It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg (2000 mg in terms of prospidium chloride) in patients with disseminated gastric cancer. In total, the study plans to include 120 patients aged 18 to 75 years inclusive, including 60 patients in the study group and 60 in the comparison group. The study consists of daily examination of patients throughout the entire period of hospitalization and subsequent visits.

NCT ID: NCT06232421 Not yet recruiting - Clinical trials for Chronic Venous Insufficiency

Clinical Study in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues, Phase I-II of the Wound Process

OLENKRON-01
Start date: June 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to estimate efficiency, tolerance, safety of "Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1" among adult patients who have purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome or chronic venous insufficiency, phase I-II of the wound process.

NCT ID: NCT06167564 Not yet recruiting - Allergy Clinical Trials

Allergy Diagnostic Test Based on Microchip Technology

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to develop a microarray-based diagnostic test system for the determination of allergen specific IgE in human blood serum.

NCT ID: NCT05520125 Not yet recruiting - Clinical trials for Segmental Fracture - Bone Loss

Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of patients with segmental bone tissue defects using mesenchymal stem cells enriched by extracellular vesicles

NCT ID: NCT05520112 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

NCT ID: NCT05218616 Not yet recruiting - Bioequivalence Clinical Trials

The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions

Start date: January 21, 2022
Phase: Phase 1
Study type: Interventional

The study is designed in accordance with the Eurasian Economic Union (EAEU) regulatory guidelines, with the aim of characterizing the bioavailability of two pharmaceutical products of sunitinib in healthy adult volunteers. Within the clinical portion of the study, each volunteer will receive a single oral dose of the test and the reference product in compliance with the generated randomization code.

NCT ID: NCT05108077 Not yet recruiting - Bladder Cancer Clinical Trials

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

Start date: March 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells